127 related articles for article (PubMed ID: 9347953)
1. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
Valladares JE; Freixas J; Alberola J; Franquelo C; Cristofol C; Arboix M
Am J Trop Med Hyg; 1997 Oct; 57(4):403-6. PubMed ID: 9347953
[TBL] [Abstract][Full Text] [Related]
2. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Valladares JE; Alberola J; Esteban M; Arboix M
Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
[TBL] [Abstract][Full Text] [Related]
5. Distribution of liposome-encapsulated antimony in dogs.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Slappendel RJ; Teske E
Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.
Tassi P; Ormas P; Madonna M; Carli S; Belloli C; De Natale G; Ceci L; Marcotrigiano GO
Res Vet Sci; 1994 Mar; 56(2):144-50. PubMed ID: 8191002
[TBL] [Abstract][Full Text] [Related]
8. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
9. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
Belloli C; Ceci L; Carli S; Tassi P; Montesissa C; De Natale G; Marcotrigiano G; Ormas P
Res Vet Sci; 1995 Mar; 58(2):123-7. PubMed ID: 7761689
[TBL] [Abstract][Full Text] [Related]
10. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
[No Abstract] [Full Text] [Related]
11. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.
Miekeley N; Mortari SR; Schubach AO
Anal Bioanal Chem; 2002 Feb; 372(3):495-502. PubMed ID: 11939540
[TBL] [Abstract][Full Text] [Related]
12. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
Belloli C; Crescenzo G; Carli S; Zaghini A; Mengozzi G; Bertini S; Ormas P
Vet J; 1999 May; 157(3):315-21. PubMed ID: 10328843
[TBL] [Abstract][Full Text] [Related]
13. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Chapman WL; Hanson WL; Alving CR; Hendricks LD
Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
[TBL] [Abstract][Full Text] [Related]
14. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
15. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
16. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
17. Owners' experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study.
de Jong MK; van Eijk D; Broere F; Piek CJ
Vet Rec; 2024 Jun; 194(11):e4089. PubMed ID: 38809570
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
19. Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.
Lugo de Yarbuh A; Añez N; Petit de Peña Y; Burguera JL; Burguera M
Ann Trop Med Parasitol; 1994 Feb; 88(1):37-41. PubMed ID: 8192513
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Mateo M; Maynard L; Vischer C; Bianciardi P; Miró G
Parasitol Res; 2009 Jul; 105(1):155-62. PubMed ID: 19238439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
